Morgan Stanley has revised its price target for Recursion Pharmaceuticals (RXRX, Financial), adjusting it from $10 to $8. Despite this adjustment, the firm maintains an Equal Weight rating for the stock.
This decision follows a detailed review conducted by Morgan Stanley, which involved an analysis of updates shared during the company’s fourth-quarter earnings and insights gained from recent discussions with Recursion's management. These interactions provided the firm with a clearer understanding of the current developments within Recursion’s pipeline.
